department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Repatha · pharmadog

pharmadog
drugs
Repatha

drug

patient view →

evolocumab

Marketedupdated 2mo ago

by $AMGN AMGEN INC

Approved

annual revenue · 2024–2024peak $2.4B

community read0 votes

indications

investigational

Hyperlipidemia

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Repatha

generic

evolocumab

indication

Atherosclerosis

phase

marketed

approved

2015-08-27

Data sources

openFDA · ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying evolocumab

phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.recruitingn=400
phase2A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)active not recruitingn=10
EP1Mechanistic Clinical Trial of PCSK9 Inhibition for AAAnot yet recruitingn=44
phase4Lipid Management in Renal Transplant Recipients Using Evolocumab.completedn=81
phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Doserecruitingn=400
phase4Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCIactive not recruitingn=2,166
phase2Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levelsrecruitingn=69
phase2YN001-004 in Patients With Coronary Atherosclerosis in Australiarecruitingn=24

more trials →